Clinical Trial Update: Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing idarubicin versus high-dose daunorubicin in acute myeloid leukemia. The current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Daunorubicin (daunorubicin)
• Idarubicin (idarubicin)

Snippet

Sponsor: Cooperative Study Group A for Hematology | Conditions: Acute Myelogenous Leukemia | Phase 3 | Status: UNKNOWN